Brief: BioArctic Says Sales Of Leqembi Totaled 13.3 Bln Yen In Q4 2024
07/02/2025 03:35
Feb 6 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC AB: SALES OF LEQEMBI® TOTALED 13.3 BILLION YEN
IN Q4
2024
Source text: ID:nWkr4k7fPW
Further company coverage: BIOAb.ST
((reuters.briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China